This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Screening for hydroxychloroquine retinopathy

Screening for hydroxychloroquine retinopathy
Reviewed by Brian Ang

1 August 2016 | Brian Ang | EYE - Vitreo-Retinal

The American Academy of Ophthalmology has updated the recommendations for screening for hydroxychloroquine retinopathy based on new scientific evidence that toxicity is not rare when hydroxychloroquine is used long-term, and that risk is dependent on the daily dose by weight. The daily dosage recommendation is <5.0mg/kg real weight. A retinal and macular examination should be performed within the first year of use, and then annual screening to commence after five years of use or earlier if there are risk factors (such as long duration of use, renal disease, concomitant tamoxifen use). Screening should be conducted with both automated perimetry and spectral domain OCT. Fundus autofluorescence and multifocal electroretinography may also provide useful information during screening. Note that fundus examination, amsler grid testing and colour vision are considered insufficient for screening. Once retinopathy has developed, the hydroxychloroquine should be discontinued upon discussion with the rheumatologist.

Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).
Marmor MF, Kellner U, Lai TYY, et al.
OPHTHALMOLOGY
2016;123:1386-94.
Share This
CONTRIBUTOR
Brian Ang

Royal Victorian Eye and Ear Hospital, Melbourne, Australia

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency